Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135759 · ClinicalTrials.gov registry record · Phase 2
Addition of Naltrexone to Methadone Taper
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00135759 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 174 participants.
The verdict
NCT00135759, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.
Interventions
- DRUG Naltrexone
- DRUG Placebo comparator
- DRUG naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135759
The ClinicalTrials.gov registry entry for NCT00135759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Naltrexone is the first listed.
NCT00135759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135759 about?
NCT00135759 is a clinical study titled "Addition of Naltrexone to Methadone Taper". There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.
What is the current status of trial NCT00135759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2005-04. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00135759?
The interventions under investigation include: Naltrexone (DRUG), Placebo comparator (DRUG), naltrexone (DRUG).
Who is sponsoring clinical trial NCT00135759?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.